Quick Answer
Cardio Diagnostics Holdings, Inc. reported Total Revenue of $14.8 thousand for fiscal year 2025.
Cardio Diagnostics Holdings, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $14.8K -57.5% |
$34.9K +104.5% |
$17.1K +1696.3% |
$950.00 +5.4% |
$901.00 | — |
| Net Income | -$6.50M +22.5% |
-$8.38M -0.1% |
-$8.38M -79.7% |
-$4.66M -651.2% |
-$620.4K | — |
| Diluted EPS | -$3.71 +60.3% |
-$9.35 -1316.7% |
-$0.66 +56.3% |
-$1.51 -184.9% |
-$0.53 | — |
| Total Assets | $7.77M -26.8% |
$10.62M +137.9% |
$4.46M -28.6% |
$6.25M +467.1% |
$1.10M | — |
| Stockholders Equity | $6.97M -27.0% |
$9.56M +223.1% |
$2.96M -31.2% |
$4.30M +302.7% |
$1.07M +1669.4% |
$60.4K |
| R&D Expense | $641.2K +181.3% |
$228.0K +57.0% |
$145.2K +258.9% |
$40.4K +28.5% |
$31.5K | — |
| Operating Income | -$6.48M +22.5% |
-$8.37M -15.5% |
-$7.24M -59.2% |
-$4.55M -633.1% |
-$620.4K | — |
| Shares Outstanding | 52.16M +3305.9% |
1.53M -92.5% |
20.54M +115.9% |
9.51M +672.1% |
1.23M | — |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $2.9K | -56.6% | -61.8% |
| Net Income | September 30, 2025 | -$1.71M | -21.4% | -1.9% |
| Diluted EPS | September 30, 2025 | -$0.98 | +43.4% | -1.0% |
| Total Assets | September 30, 2025 | $8.79M | +96.1% | -15.5% |
| Stockholders Equity | September 30, 2025 | $8.15M | +121.1% | -16.2% |
| R&D Expense | March 31, 2025 | $2.2K | -79.7% | -58.1% |
| Operating Income | September 30, 2025 | -$1.71M | -21.5% | -2.0% |
| Shares Outstanding | September 30, 2025 | 1.77M | -94.2% | +1.5% |
- Cardio Diagnostics Holdings, Inc. reported Total Revenue of $14.8 thousand for fiscal year 2025.
- Cardio Diagnostics Holdings, Inc. showed a decrease of -57.5% in Total Revenue compared to the prior fiscal year.
- Cardio Diagnostics Holdings, Inc. reported Net Income of -$6.50 million for fiscal year 2025.
- Cardio Diagnostics Holdings, Inc. showed an increase of +22.5% in Net Income compared to the prior fiscal year.
- Cardio Diagnostics Holdings, Inc. reported Diluted EPS of $3.71 per share (loss) for fiscal year 2025.
- Cardio Diagnostics Holdings, Inc. showed an increase of +60.3% in Diluted EPS compared to the prior fiscal year.
- Cardio Diagnostics Holdings, Inc. reported Total Assets of $7.77 million for fiscal year 2025.
- Cardio Diagnostics Holdings, Inc. showed a decrease of -26.8% in Total Assets compared to the prior fiscal year.
- Cardio Diagnostics Holdings, Inc. reported Stockholders Equity of $6.97 million for fiscal year 2025.
- Cardio Diagnostics Holdings, Inc. showed a decrease of -27.0% in Stockholders Equity compared to the prior fiscal year.
- Cardio Diagnostics Holdings, Inc. reported R&D Expense of $641.2 thousand for fiscal year 2025.
- Cardio Diagnostics Holdings, Inc. showed an increase of +181.3% in R&D Expense compared to the prior fiscal year.
- Cardio Diagnostics Holdings, Inc. reported Operating Income of -$6.48 million for fiscal year 2025.
- Cardio Diagnostics Holdings, Inc. showed an increase of +22.5% in Operating Income compared to the prior fiscal year.
- Cardio Diagnostics Holdings, Inc. reported Shares Outstanding of 1.83 million shares for fiscal year 2025.
- Cardio Diagnostics Holdings, Inc. showed a decrease of -96.5% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: